Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications

Crit Rev Oncol Hematol. 2021 May:161:103325. doi: 10.1016/j.critrevonc.2021.103325. Epub 2021 Apr 6.

Abstract

Near-InfraRed PhotoImmunoTherapy (NIR-PIT) is a novel cancer-targeted treatment effected by a chemical conjugation between a photosensitiser (e.g. the NIR phthalocyanine dye IRDye700DX) and a cancer-targeting moiety (e.g. a monoclonal antibody, moAb). Delivery of a conjugate in vivo leads to accumulation at the tumour cell surface by binding to cell surface receptors or antigens. Upon deployment of focal NIR-light, irradiation of the conjugate results in a rapid, targeted cell death. However, the mechanisms of action to produce the cytotoxic effects have yet to be fully understood. Herein, we bring together the current knowledge of NIR-PIT from preclinical and clinical studies in a variety of cancers highlighting the key unanswered research questions. Furthermore, we discuss how to enhance the local control of solid cancers using this novel treatment regimen.

Keywords: Clinical trials; In vitro; In vivo; Local control; Monoclonal antibodies; Near-InfraRed fluorophores; PhotoImmunoTherapy; Solid cancers.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal
  • Cell Line, Tumor
  • Humans
  • Immunoconjugates*
  • Immunotherapy
  • Neoplasms* / therapy
  • Photosensitizing Agents
  • Phototherapy

Substances

  • Antibodies, Monoclonal
  • Immunoconjugates
  • Photosensitizing Agents